Cancer Treatment Reviews
Volume 37, Issue 2 , Pages 89-96 , April 2011

Adjuvant radiotherapy after radical prostatectomy: Evidence and analysis

  • Ann Raldow

      Affiliations

    • Yale School of Medicine, New Haven, CT, United States
    • ,
  • Daniel A. Hamstra

      Affiliations

    • Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, MI, United States
    • ,
  • Sung N. Kim

      Affiliations

    • Department of Radiation Oncology, Cancer Institute of New Jersey, NJ, United States
    • Robert Wood Johnson Medical School, New Brunswick, NJ, United States
    • University of Medicine and Dentistry of New Jersey, New Brunswick, NJ, United States
    • ,
  • James B. Yu

      Affiliations

    • Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT, United States
    • Corresponding Author InformationCorresponding author. Tel.: +1 2037855703.

Received 6 April 2010 ,Revised 28 June 2010 ,Accepted 4 July 2010.

References 

  1. Jemal A, et al. Cancer statistics 2009. CA Cancer J Clin. 2009;59(4):225–249
  2. Underwood W, et al. Racial treatment trends in localized/regional prostate carcinoma: 1992–1999. Cancer. 2005;103(3):538–545
  3. Bill-Axelson A, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005;352(19):1977–1984
  4. Cooperberg MR, et al. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J Urol. 2004;171(4):1393–1401
  5. Klein EA, et al. Surgeon experience is strongly associated with biochemical recurrence after radical prostatectomy for all preoperative risk categories. J Urol. 2008;179(6):2212–2216discussion 2216-7
  6. Ward JF, et al. The impact of surgical approach (nerve bundle preservation versus wide local excision) on surgical margins and biochemical recurrence following radical prostatectomy. J Urol. 2004;172(4 Pt 1):1328–1332
  7. Bott SR, et al. Radical prostatectomy: pathology findings in 1001 cases compared with other major series and over time. BJU Int. 2005;95(1):34–39
  8. Walz J, et al. Risk-adjusted hazard rates of biochemical recurrence for prostate cancer patients after radical prostatectomy. Eur Urol. 2009;55(2):412–419
  9. Touijer K, et al. Oncologic outcome after laparoscopic radical prostatectomy: 10 years of experience. Eur Urol. 2009;55(5):1014–1019
  10. Roehl KA, et al. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3478 consecutive patients: long-term results. J Urol. 2004;172(3):910–914
  11. Swanson GP, Riggs M, Hermans M. Pathologic findings at radical prostatectomy: risk factors for failure and death. Urol Oncol. 2007;25(2):110–114
  12. Vis AN, Schroder FH, van der Kwast TH. The actual value of the surgical margin status as a predictor of disease progression in men with early prostate cancer. Eur Urol. 2006;50(2):258–265
  13. Dahl DM, et al. Pathologic outcome of laparoscopic and open radical prostatectomy. Urology. 2006;68(6):1253–1256
  14. Katz MS, et al. Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. J Clin Oncol. 2003;21(3):483–489
  15. Freedland SJ, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294(4):433–439
  16. Pound CR, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281(17):1591–1597
  17. Freedland SJ, et al. Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality. J Urol. 2006;176(4 Pt 1):1404–1408
  18. Bolla M, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet. 2005;366(9485):572–578
  19. Thompson IM, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol. 2009;181(3):956–962
  20. Wiegel T, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol. 2009;27(18):2924–2930
  21. King CR, Kapp DS. Radiotherapy after prostatectomy: is the evidence for dose escalation out there?. Int J Radiat Oncol Biol Phys. 2008;71(2):346–350
  22. Stephenson AJ, et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA. 2004;291(11):1325–1332
  23. Stephenson AJ, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 2007;25(15):2035–2041
  24. Trock BJ, et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA. 2008;299(23):2760–2769
  25. Van der Kwast TH, et al. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol. 2007;25(27):4178–4186
  26. Parker C, et al. Radiotherapy and androgen deprivation in combination after local surgery (RADICALS): a new Medical Research Council/National Cancer Institute of Canada phase III trial of adjuvant treatment after radical prostatectomy. BJU Int. 2007;99(6):1376–1379
  27. Eisenberg ML et al. Prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomy. Eur Urol 2009 Apr 3 [Epub ahead of print].
  28. Supiot S, et al. A phase I trial of pre-operative radiotherapy for prostate cancer: clinical and translational studies. Radiother Oncol. 2008;88(1):53–60
  29. Swanson GP, et al. Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol. 2007;25(16):2225–2229
  30. Jereczek-Fossa BA, Orecchia R. Evidence-based radiation oncology: definitive, adjuvant and salvage radiotherapy for non-metastatic prostate cancer. Radiother Oncol. 2007;84(2):197–215
  31. Fonteyne V, et al. Late radiotherapy-induced lower intestinal toxicity (RILIT) of intensity-modulated radiotherapy for prostate cancer: the need for adapting toxicity scales and the appearance of the sigmoid colon as co-responsible organ for lower intestinal toxicity. Radiother Oncol. 2007;84(2):156–163
  32. De Meerleer GO, et al. Intensity-modulated radiation therapy for prostate cancer: late morbidity and results on biochemical control. Radiother Oncol. 2007;82(2):160–166
  33. Krengli M, et al. Intraoperative radiotherapy during radical prostatectomy for locally advanced prostate cancer: technical and dosimetric aspects. Int J Radiat Oncol Biol Phys. 2010;76(4):1073–1077
  34. Rocco B, et al. Intraoperative radiotherapy during radical prostatectomy for intermediate-risk to locally advanced prostate cancer: treatment technique and evaluation of perioperative and functional outcome vs standard radical prostatectomy, in a matched-pair analysis. BJU Int. 2009;104(11):1624–1630
  35. Orecchia R, et al. Intraoperative radiotherapy for locally advanced prostate cancer: treatment technique and ultrasound-based analysis of dose distribution. Anticancer Res. 2007;27(5B):3471–3476
  36. Saracino B, et al. Phase I-II study of intraoperative radiation therapy (IORT) after radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;71(4):1049–1056
  37. Van Cangh PJ. The increase in minimally invasive endourology – a tribute to excellence and a plea for thoughtful restraint. J Urol. 1996;156(4):1411
  38. Moinpour CM, et al. Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy. J Clin Oncol. 2008;26(1):112–120
  39. Poortmans P, et al. Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group. Radiother Oncol. 2007;84(2):121–127
  40. Michalski JM, et al. Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2010;76:361–368
  41. Wiltshire KL, et al. Anatomic boundaries of the clinical target volume (prostate bed) after radical prostatectomy. Int J Radiat Oncol Biol Phys. 2007;69(4):1090–1099
  42. Sidhom MA, et al. Post-prostatectomy radiation therapy: consensus guidelines of the Australian and New Zealand Radiation Oncology Genito-Urinary Group. Radiother Oncol. 2008;88(1):10–19
  43. Miralbell R, et al. Endorectal MRI assessment of local relapse after surgery for prostate cancer: a model to define treatment field guidelines for adjuvant radiotherapy in patients at high risk for local failure. Int J Radiat Oncol Biol Phys. 2007;67(2):356–361
  44. Silverman JM. Krebs, TL. MR imaging evaluation with a transrectal surface coil of local recurrence of prostatic cancer in men who have undergone radical prostatectomy. AJR Am J Roentgenol. 1997;168(2):379–385
  45. Sella T, et al. Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology. 2004;231(2):379–385
  46. Wang K, et al. The uncertainties in target localization for prostate and prostate-bed radiotherapy with Calypso 4D. Int J Radiat Oncol Biol Phys. 2009;75(3):S594
  47. Schiffner DC, et al. Daily electronic portal imaging of implanted gold seed fiducials in patients undergoing radiotherapy after radical prostatectomy. Int J Radiat Oncol Biol Phys. 2007;67(2):610–619
  48. Nath SK Nov 23 [Epub ahead of print]. Toxicity analysis of postoperative image-guided intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2009 Nov 23 [Epub ahead of print].
  49. Pollack A, et al. Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002;53(5):1097–1105
  50. Zietman AL, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005;294(10):1233–1239
  51. Kupelian P, et al. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995. Int J Radiat Oncol Biol Phys. 2005;61(2):415–419
  52. Ost P, et al. Adjuvant high-dose intensity-modulated radiotherapy after radical prostatectomy for prostate cancer: clinical results in 104 patients. Eur Urol. 2009;56(4):669–675
  53. Al-Mamgani A, et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;72(4):980–988
  54. Kuban DA, et al. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70(1):67–74
  55. Dearnaley DP, et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer. 2005;92(3):488–498
  56. Cancer facts and figures, 2009.
  57. Schulman KL, Kohles J. Economic burden of metastatic bone disease in the US. Cancer. 2007;109(11):2334–2342
  58. Zubek VB, Konski A. Cost effectiveness of risk-prediction tools in selecting patients for immediate post-prostatectomy treatment. Mol Diagn Ther. 2009;13(1):31–47
  59. EuroQol – a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990;16(3):199–208.
  60. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med. 1988;318(26):1728–1733
  61. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ. 1995;310(6977):452–454
  62. Cordell WH. Number needed to treat (NNT). Ann Emerg Med. 1999;33(4):433–436
  63. L’Abbe KA, Detsky AS, O’Rourke K. Meta-analysis in clinical research. Ann Intern Med. 1987;107(2):224–233
  64. Bill-Axelson A, et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst. 2008;100(16):1144–1154
  65. Thompson IM, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA. 2006;296(19):2329–2335

PII: S0305-7372(10)00109-X

doi: 10.1016/j.ctrv.2010.07.001

Cancer Treatment Reviews
Volume 37, Issue 2 , Pages 89-96 , April 2011

Article Tools